title: Antiviral activity of type I interferons and interleukins 29 and 28a (type III interferons) against Apeu virus.
abstract: Interferons (IFNs) are cytokines with important immunomodulatory activity in vertebrates. Although type I IFNs and interleukins (IL) 29 and 28a (type III IFNs) bind to different cellular receptors and have distinct structures, most of their biological activities are redundant. Apeu virus (APEUV) is a member of the Bunyaviridae family isolated from the Brazilian rain forest. In this paper we evaluated the antiviral activity of type I and type III IFNs against APEUV. All tested IFNs were able to induce an antiviral state against the virus in a dose-dependent way. The activity of type III IFNs did not need the presence of type I IFNs. Mixing both types of IFNs did not improve the biological activity of each type alone. The tested IFNs were also able to protect human peripheral blood mononuclear cells from infection. IFN alpha2, IFN beta, IL-29 and IL-28a induced the expression of 2',5'-oligoadenylate synthetase (2'5'OAS) and 6-16 genes. Although MxA gene was related to antiviral activity against Bunyaviruses, there was no induction of MxA in our model. We were able to show activity of type I and type III IFNs against a RNA virus, and that this activity is not dependent on MxA gene.
authors.affiliation: Laboratório de Vírus, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627 Pampulha, Belo Horizonte CEP 31270-901, MG, Brazil.
authors.forename: Gabriel Magno de Freitas
authors.initials: GM
authors.lastname: Almeida
authors.forename: Danilo Bretas
authors.initials: DB
authors.lastname: de Oliveira
authors.forename: Cintia Lopes de Brito
authors.initials: CL
authors.lastname: Magalhães
authors.forename: Cláudio Antônio
authors.initials: CA
authors.lastname: Bonjardim
authors.forename: Paulo César Peregrino
authors.initials: PC
authors.lastname: Ferreira
authors.forename: Erna Geessien
authors.initials: EG
authors.lastname: Kroon
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000276:immunology* / Q000494:pharmacology; D002044:Bunyaviridae Infections / Q000188:drug therapy* / Q000821:virology; D002478:Cells, Cultured; D002522:Chlorocebus aethiops; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007370:Interferon Type I / Q000276:immunology* / Q000494:pharmacology; D007372:Interferons; D007378:Interleukins / Q000276:immunology* / Q000494:pharmacology; D007963:Leukocytes, Mononuclear / Q000187:drug effects; D016851:Orthobunyavirus / Q000187:drug effects / Q000276:immunology; D014709:Vero Cells; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D007370:Interferon Type I; D007372:Interferons; D007378:Interleukins; C000624353:interferon-lambda, human; D000095022:Interferon Lambda